FDA Approves Rectal Cancer Immunotherapy Backed by Swim Across America
🤖 AI-generated content — The title and summary were produced automatically by artificial intelligence, without human editorial review.
The FDA granted accelerated approval to Jemperli (dostarlimab) on Oct. 19, 2026, for certain patients with locally advanced rectal cancer. MSK trials led by Luis Diaz Jr. and Andrea Cercek found the immunotherapy could eliminate tumors without chemotherapy, radiation or surgery.
Continue in the app — vote & join in ➔Source: SwimSwam · via ahirlevel.hu